TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Ovid Therapeutics
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics announced a CEO succession plan with Meg Alexander becoming CEO on January 1, 2026, and Dr. Jeremy M. Levin transitioning to Executive Chair. The company reported positive Phase 1 results for OV329, a next-generation GABA-AT inhibitor, and continues advancing its KCC2 direct activator portfolio.

Insights
AMZN   positive

Extended post-earnings surge, climbing 4.7% after Friday's 9.6% rally


OVID   positive

Demonstrated strong clinical trial results for OV329, completed a significant private placement raising $175 million, progressing multiple drug development programs, and executing a strategic leadership transition